Patents Assigned to ImmuLogic Pharmaceutical Corporation
  • Patent number: 5843672
    Abstract: Isolated nucleic acids encoding allergens of Canis familiaris, Can f I or Can f II, are disclosed. A cDNA encoding a peptide having a Can f I activity and a predicted molecular weight of about 19,200 daltons is also described. A cDNA encoding a peptide having Can f II activity and a predicted molecular weight of about 18,200 daltons is also disclosed. The nucleic acids can be used as probes to detect the presence of Can f I or Can f II nucleic acid in a sample or for the recombinant production of peptides having a Can f I or Can f II activity. Peptides having a Can f I or Can f II activity can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to dog dander.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 1, 1998
    Assignee: ImmuLogic Pharmaceutical Corporation
    Inventors: Jay P. Morgenstern, Andrzej Konieczny, Christine B. Bizinkauskas, Andrew W. Brauer
  • Patent number: 5820862
    Abstract: The present invention provides isolated peptides of the major protein allergens of the genus Dermatophagoides. Peptides within the scope of the invention comprises at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen selected from the allergens Der p I, Der p II, Der f I, or Der f II. The invention also pertains to modified peptides having similar or enhanced therapeutic properties as the corresponding, naturally-occurring allergen or portion thereof, but having reduced side effects. The invention further provides nucleic acid sequences coding for peptides of the invention. Methods of treatment or of diagnosis of sensitivity to house dust mites in an individual and therapeutic compositions comprising one or more peptides of the invention are also provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 13, 1998
    Assignee: Immulogic Pharmaceutical Corporation
    Inventors: Richard D. Garman, Julia L. Greenstein, Mei-chang Kuo, Bruce L. Rogers, Henry M. Franzen, Xian Chen, Sean Evans, Ze'ev Shaked
  • Patent number: 5776761
    Abstract: Antigen E or Amb a I of ragweed pollen has been shown to be a family or families of proteins. cDNAs encoding Amb a I, the major human allergen of ragweed and Amb a II, peptides derived from Amb a I or Amb a II, antibodies against the peptides; and methods of treating individuals for sensitivity to ragweed are disclosed.
    Type: Grant
    Filed: December 29, 1993
    Date of Patent: July 7, 1998
    Assignees: ImmuLogic Pharmaceutical Corporation, the University of North Carolina at Chapel Hill
    Inventors: Bruce Rogers, David G. Klapper, Thorunn Rafnar, Mei-chang Kuo
  • Patent number: 5773002
    Abstract: The present invention features isolated DNA encoding allergens of Dermatophagoides (house dust mites) particularly of the species Dermatophagoides farinae and Dermatophagoides pteronyssinus, which are protein allergens or peptides which include at least one epitope of the protein allergen. In particular, the invention provides DNA encoding the major D. farinae allergens, Der f I and Der f II and DNA encoding the major D. pteronvssinus allergens, Der p I and Der p II. The present invention further relates to proteins and peptides encoded by the isolated D. farinae and D. pteronvssinus DNA, including proteins containing sequence polymorphisms. In addition, the proteins or peptides encoded by the isolated DNA, their use a diagnostic and therapeutic reagents and methods of diagnosing and treating sensitivity to house dust mite allergens, are disclosed.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: June 30, 1998
    Assignees: The Institute of Child Health Research, Immulogic Pharmaceutical Corporation
    Inventors: Wayne R. Thomas, Kaw-Yan Chua
  • Patent number: 5770202
    Abstract: The present invention features isolated DNA encoding allergens of Dermatophagoides (house dust mites) particularly of the species Dermatophagoides farinae and Dermatophagoides pteronyssinus, which are protein allergens or peptides which include at least one epitope of the protein allergen. In particular, the invention provides DNA encoding the major D. farinae allergens, Der f I and Der f II and DNA encoding the major D. pteronyssinus allergens, Der p I and Der p II. The present invention further relates to proteins and peptides encoded by the isolated D. farinae and D. pteronyssinus DNA, including proteins containing sequence polymorphisms. In addition, the proteins or peptides encoded by the isolated DNA, their use a diagnostic and therapeutic reagents and methods of diagnosing and treating sensitivity to house dust mite allergens, are disclosed.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: June 23, 1998
    Assignees: The Institute for Child Health Research, Immulogic Pharmaceutical Corporation
    Inventors: Wayne R. Thomas, Kaw-Yan Chua
  • Patent number: 5710126
    Abstract: The present invention provides isolated peptides of Lol p V, a major protein allergen of the species Lolium perenne. Therapeutic peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen of Lol p V. Diagnostic peptides within the scope of the invention bind IgE. The invention also provides modified peptides having similar or enhanced therapeutic properties as the corresponding, naturally-occurring allergen or portion thereof, but having reduced side effects. The invention further provides nucleic acid sequences coding for peptides of the invention. Methods of treatment or diagnosis of sensitivity to Lol p V or an allergen immunologically related to Lol p V in an individual. Therapeutic compositions comprising one or more peptides of the invention are also provided.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: January 20, 1998
    Assignee: ImmuLogic Pharmaceutical Corporation
    Inventors: Irwin J. Griffith, Mei-chang Kuo, Mohammad Luqman
  • Patent number: 5698204
    Abstract: Antigen E or Amb a I of ragweed pollen has been shown to be a family or families of proteins. cDNAs encoding Amb a I, the major human allergen of ragweed and Amb a II, peptides derived from Amb a I or Amb a II, antibodies against the peptides; and methods of treating individuals for sensitivity to ragweed are disclosed.
    Type: Grant
    Filed: August 15, 1994
    Date of Patent: December 16, 1997
    Assignees: ImmuLogic Pharmaceutical Corporation, University of North Carolina at Chapel Hill
    Inventors: Bruce Rogers, David G. Klapper, Thorunn Rafnar, Mei-chang Kuo
  • Patent number: 5691167
    Abstract: The present invention provides a nucleic acid having a nucleotide sequence coding for Sor h I, a major allergen of Sorghum halepense, and fragments thereof. The present invention also provides purified Sor h I or at least one fragment thereof, produced in a host cell transformed with a nucleic acid sequence coding for Sor h I, or at least one fragment thereof and fragments of Sor h prepared synthetically. Sor h I and fragments thereof are useful for diagnosing, treating, and preventing allergy to Johnson grass pollen.
    Type: Grant
    Filed: December 29, 1993
    Date of Patent: November 25, 1997
    Assignees: The University of Melbourne, ImmuLogic Pharmaceutical Corporation
    Inventors: Asil Avjioglu, Mohan Bir Singh, Robert Bruce Knox
  • Patent number: 5552142
    Abstract: The present invention features isolated DNA encoding allergens of Dermatophagoides (house dust mites) particularly of the species Dermatophagoides farinae and Dermatophagoides pteronyssinus, which are protein allergens or peptides which include at least one epitope of the protein allergen. In particular, the invention provides DNA encoding the major D, farinae allergens, Der f I and Der f II and DNA encoding the major D. pteronyssinus allergens, Der p I and Der p II. The present invention further relates to proteins and peptides encoded by the isolated D. farinae and D. pteronyssinus DNA, including proteins containing sequence polymorphisms. In addition, the proteins or peptides encoded by the isolated DNA, their use a diagnostic and therapeutic reagents and methods of diagnosing and treating sensitivity to house dust mite allergens, are disclosed.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: September 3, 1996
    Assignee: Immulogic Pharmaceutical Corporation
    Inventors: Wayne R. Thomas, Kaw-Yan Chua
  • Patent number: 5480972
    Abstract: The present invention provides a nucleic acid having a nucleotide sequence coding for Sor h I, a major allergen of Sorghum halepense, and fragments thereof. The present invention also provides purified Sor h I or at least one fragment thereof, produced in a host cell transformed with a nucleic acid sequence coding for Sor h I, or at least one fragment thereof and fragments of Sor h prepared synthetically. Sor h I and fragments thereof are useful for diagnosing, treating, and preventing allergy to Johnson grass pollen.
    Type: Grant
    Filed: October 30, 1992
    Date of Patent: January 2, 1996
    Assignees: The University of Melbourne, ImmuLogic Pharmaceutical Corporation
    Inventors: Asil Avjioglu, Mohan B. Singh, Robert B. Knox
  • Patent number: 5407802
    Abstract: Two subsets of Islet Cell Autoantibodies (ICA), termed restricted and non-restricted, have been identified. The expression of non-restricted ICA correlates with progression to type I diabetes, indicating that these individuals are at much greater risk than are individuals expressing restricted ICA. Differentiation between restricted or non-restricted ICA allows for more accurate prognosis of the development of type I diabetes. Restricted ICA react with beta cells of human and rat islets but not mouse, whereas non-restricted ICA react with humans rat and mouse islets. Restricted ICA can be substantially completely absorbed by incubation with glutamic acid decarboxylase (GAD), whereas non-restricted ICA are partially or not at all absorbed by GAD. Restricted ICA react in a Stiff-Man Syndrome fashion including staining GABAergic neurons in brain sections and western blots of brain extracts, whereas non-restricted ICA does not react with either brain sections nor with GAD antigen in western blots.
    Type: Grant
    Filed: December 26, 1991
    Date of Patent: April 18, 1995
    Assignee: Immulogic Pharmaceutical Corporation
    Inventors: George S. Eisenbarth, Roberto Gianani